Earnings Summary

Verona Pharma Plc - Adr’s revenue fell -100% since last year same period to $0Mn in the Q4 2023. On a quarterly growth basis, Verona Pharma Plc - Adr has generated NaN% jump in its revenue since last 3-months.

Verona Pharma Plc - Adr’s net profit fell -36.4% since last year same period to $-14.25Mn in the Q4 2023. On a quarterly growth basis, Verona Pharma Plc - Adr has generated 2.94% jump in its net profits since last 3-months.

Verona Pharma Plc - Adr’s net profit margin fell -Inf% since last year same period to -Inf% in the Q4 2023. On a quarterly growth basis, Verona Pharma Plc - Adr has generated NaN% jump in its net profit margins since last 3-months.

Verona Pharma Plc - Adr’s earning per share (EPS) estimates for the current quarter stand at -0.25 - a 3.85% jump from last quarter’s estimates.

Verona Pharma Plc - Adr’s earning per share (EPS) estimates for the current year stand at -0.25.

Verona Pharma Plc - Adr’s earning per share (EPS) fell -12.5% since last year same period to -0.18 in the Q4 2023. This indicates that the Verona Pharma Plc - Adr has generated -12.5% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Verona Pharma Plc - Adr’s return on assets (ROA) stands at -0.15.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Verona Pharma Plc - Adr’s return on equity (ROE) stands at -0.23.